Dr. Veltri served on the faculty
of microbiology and surgery of WVU from 1969-80, where his research
covered the areas of infectious diseases, immunology, and cancer
biomarkers. Dr. Veltri developed a fee for service clinical immunology
and virology diagnostic testing service for the WVU hospital's
department of clinical pathology that generated about $100,000
in revenue by 1980. Teaching responsibilities included medical,
dental, nursing and graduate level students in areas of microbiology,
virology, and cancer biology. He also trained and served as advisor
for eight MS and seven Ph.D. graduate students of microbiology
during his tenure at WVU. A total of seventeen Medical, Dental,
and Medical Technology students did research clerkships in Dr.
Veltri's laboratory during his tenure at WVU. He obtained more
than $1.0 Million in extramural research funding while at WVU.
Served as President of the WVU chapter of Sigma Xi and also received
an outstanding teacher's award in 1976.
In 1981-84 Dr. Veltri established
an R&D team, which developed the first diagnostic application
for liposomes that consisted of rapid (1-2 minutes) and sensitive
(10-fold improvement to ng/ml) slide co-agglutination diagnostic
kits for infectious and rheumatologic diseases. Three Class II,
FDA approved 510K products were transferred to manufacturing and
released to market based upon a proprietary and patented co-agglutination
technology that employed a proprietary method to prepare protein-A
coated Liposomes and combine them with antibody coated latex particles.
The three FDA approved tests were for Streptococcal Group A, Rheumatoid
arthritis, and Infectious Mononucleosis.
In 1984, Dr. Veltri founded the
American Biotechnology Company in Rockville, MD (acquired by Theracel
Corporation in 1988). We discovered two unique classes of L-Ascorbic
acid derivatives based upon the use of an Aldol and Michael addition
series of modifications performed at the C-2 position of the molecule
(see patents 1,2,4,5, 7 and 8 above). These small molecules were
all of very low toxicity, water-soluble and demonstrated a variety
of biological activities including anti-cancer, anti-infectious
and anti-inflammatory activity.
In 1996, Dr. Veltri and his
R&D team commercialized the first statistical-based (Logistic
Regression model) and patented algorithm to predict prostate cancer
post-operative stage based upon pre-treatment quantitative biopsy
pathology as well as DNA ploidy and quantitative nuclear grade
information determined by image analysis. The product was Trademarked
“UroScoreTM”, a term suggested by Dr. Veltri. There
are three publications (reference # 51, 77 and 88 in the above
bibliography) on the subject.